Galena Biopharma (GALE) Announces Presentation of Encouraging GALE-401 Phase 2 Data in Thrombocytosis
Tweet Send to a Friend
Galena Biopharma (NASDAQ: GALE) announced that data from the Company's Phase 2 clinical trial of GALE-401 was presented at the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
